PETALING JAYA: The private Covid-19 vaccination rollout may now be challenging as many people in the Klang Valley have already received their doses, says the Association of Private Hospitals Malaysia (APHM).
Its president Datuk Dr Kuljit Singh said the predicament of private facilities is worsened by the fact that only one vaccine brand is allowed for commercial purchase.
“Currently private healthcare will be purchasing a particular brand and the ceiling price of the sale to the public will be announced soon.
"We hope this will further enhance the vaccination process and an earlier herd immunity could be achieved.
“However, there may be a bit of a challenge to private healthcare in promoting private vaccination as the government has dealt with the vaccination process very efficiently and progressively has ramped up the number of vaccinations per day.
“This will be less attractive for anyone to seek private vaccination at a cost and additionally it’s only confined to a particular brand,” he said in a statement on Thursday (Aug 5).
He added that as such, private vaccination may only be beneficial or attractive to people who are based outside the Klang Valley.
“Currently the main purpose of getting the vaccination is defeated in a private setting, particularly in the Klang Valley, as the government has provided easy access to be vaccinated.
“Private vaccination in private healthcare facilities inclusive of private hospitals and general practitioners will only benefit the people outside of Klang Valley for now, and for those who insist on the particular brand that is allowed to be sold,” he said.
As at Aug 4, about 98% of adults living in the Klang Valley have received at least one dose, with nearly half of them having been fully vaccinated.
Dr Kuljit expressed hope that more types of Covid-19 vaccines could be opened up to private vaccination purchase.
“This is so that it will cater to those who wish to be vaccinated in less crowded environments, and perhaps in the near future when booster doses may be mandated for continuous immunity to the virus,” he said.